Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Ekso Bionics Holdings (EKSO) EBT (2016 - 2025)

Historic EBT for Ekso Bionics Holdings (EKSO) over the last 14 years, with Q3 2025 value amounting to -$1.4 million.

  • Ekso Bionics Holdings' EBT rose 4775.57% to -$1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.3 million, marking a year-over-year increase of 580.51%. This contributed to the annual value of -$10.7 million for FY2024, which is 3039.44% up from last year.
  • Ekso Bionics Holdings' EBT amounted to -$1.4 million in Q3 2025, which was up 4775.57% from -$4.0 million recorded in Q2 2025.
  • Ekso Bionics Holdings' 5-year EBT high stood at -$1.4 million for Q3 2025, and its period low was -$4.6 million during Q4 2021.
  • Moreover, its 5-year median value for EBT was -$3.4 million (2021), whereas its average is -$3.4 million.
  • Over the last 5 years, Ekso Bionics Holdings' EBT had its largest YoY gain of 4775.57% in 2025, and its largest YoY loss of 6770.44% in 2025.
  • Ekso Bionics Holdings' EBT (Quarter) stood at -$4.6 million in 2021, then grew by 1.87% to -$4.5 million in 2022, then rose by 21.92% to -$3.5 million in 2023, then soared by 34.88% to -$2.3 million in 2024, then soared by 37.96% to -$1.4 million in 2025.
  • Its EBT was -$1.4 million in Q3 2025, compared to -$4.0 million in Q2 2025 and -$3.5 million in Q1 2025.